After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?

In April of this year, Pfizer (PFE.US) stock price fell to its lowest point since January 2013. As of the closing price on July 1, the stock has risen by about 11% since then; After falling to an 11-year low, Pfizer has been consolidating for several months. So, should you buy or sell Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag from the cooling of its COVID-19 products and actively promote the development of non-COVID-19 drug business. Recently, the company announced positive trial results of two potential anticancer drugs, but also closed a gene therapy project, and the company's stock price continues to trade sideways. In a study, patients who received Pfizer Elrex

Zhitong FinanceJul 3 15:22

(NVAX) - Analyzing Novavax's Short Interest

Novavax's (NYSE:NVAX) short percent of float has risen 3.9% since its last report. The company recently reported that it has 39.71 million shares sold short, which is 34.36% of all regular shares that

BenzingaJul 3 03:30

COVID Infections Could Be Seeing a Summer Surge Based on CDC Data

Seeking AlphaJul 2 23:49

Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine

Novavax (NVAX) said Tuesday that it has submitted an application with Health Canada for authorization of its 2024-2025 Formula Covid-19 vaccine for individuals 12 years and older. The updated vaccine

MT NewswiresJul 2 21:57

Express News | Novavax Inc - Intends to Have Its Vaccine Available in Canada for Immediate Release Post-Authorization

BreakingsJul 2 20:30

Express News | Novavax Submits Application to Health Canada for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine

BreakingsJul 2 20:30